Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors-Reference-Cited by-同舟云学术

Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors

Published:2021-12-30 Issue: Volume: Page:
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Intl Journal of Cancer

Author:

Baek Yeon‐Hee¹^ORCID,Kang Eun Joo²,Hong Soojung³,Park Sohee¹,Kim Ju Hwan¹,Shin Ju‐Young¹⁴⁵

Affiliation:

1. School of Pharmacy Sungkyunkwan University Suwon South Korea

2. Division of Medical Oncology, Department of Internal Medicine Korea University Guro Hospital Seoul South Korea

3. Department of Internal Medicine, Division of Medical Oncology National Health Insurance Service Ilsan Hospital Goyang South Korea

4. Department of Biohealth Regulatory Science Sungkyunkwan University Suwon South Korea

5. Samsung Advanced Institute for Health Sciences & Technology (SAIHST) Sungkyunkwan University Seoul South Korea

Funder

Ministry of Food and Drug Safety

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.33892

Reference36 articles.

1. Immune checkpoint inhibitors‐related cardiotoxicity;Konala VM;Am J Ther,2019

2. Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

3. The Gastric and Intestinal Microbiome: Role of Proton Pump Inhibitors

4. The Acidic Tumor Microenvironment as a Driver of Cancer

5. The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors;Bellone M;Onco Targets Ther,2013

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FGL1: a novel biomarker and target for non-small cell lung cancer, promoting tumor progression and metastasis through KDM4A/STAT3 transcription mechanism;Journal of Experimental & Clinical Cancer Research;2024-08-01

2. Gut Microbiota Are a Novel Source of Biomarkers for Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC);Cancers;2024-05-09

3. Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data;Journal of Cancer Research and Clinical Oncology;2024-04-10

4. Diagnosis and management of immune mediated liver injury from checkpoint inhibitors;Current Opinion in Gastroenterology;2024-02-15

5. Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: Analysis of Health Insurance Review and Assessment data;2024-02-12